sur INVENTIVA (EPA:IVA)
Inventiva Announces Schedule for 2025 Financial Results
Inventiva, a clinical-stage biopharmaceutical firm, has announced the release of its 2025 full-year financial results. The report will be published on March 30, 2026, after market close in the United States. This French and American-listed company, recognized for developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), is organizing a conference call the following day. Stakeholders can participate in the call on March 31, 2026, at 8:00 am New York time, and 2:00 pm Paris time. Advanced phone registration is required to ask questions.
The conference call will include a Q&A and will be accessible through a live webcast on Inventiva's website. Additionally, a replay of the event will be available post-conference for those unable to attend live. This announcement indicates Inventiva's ongoing commitment to transparency and stakeholder engagement.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de INVENTIVA